Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum

About this update from Taysha Gene Therapies, Inc.

[{"type":"text","content":"\nLifeSci Genetics Medicine Conference on June 22, 2021 at 10:00 am ET\n\nLSX Biotech Growth CEO Forum on June 22, 2021 at 1:10 pm ET\n\n DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats at the LifeSci Genetics Medicine Conference and LSX Biotech Growth CEO Forum.\n\nConferences Details:\n\n\n\nEvent:\n\n\n \n\n\nLifeSci Genetics Medicine Conference\n\n\n\n\n\nDate:\n\n\n \n\n\nTuesday, June 22, 2021\n\n\n\n\n\nTime:\n\n\n \n\n\n10:00 am ET\n\n\n\n\n\nFormat:\n\n\n \n\n\nFireside chat\n\n\n\n\n\nParticipants:\n\n\n \n\n\nRA Session II, President, Founder and CEO\n\n\n\n\n\n \n\n\nDr. Suyash Prasad, Chief Medical Officer and Head of R&D\n\n\n\n\n\n \n\n\nKamran Alam, Chief Financial Officer\n\n\n\n\n\n \n\n\n \n\n\n\n\n\nEvent:\n\n\n \n\n\nLSX Biotech Growth CEO Forum\n\n\n\n\n\nTopic:\n\n\n \n\n\n“Too Much of a Good Thing Can be Wonderful: Optimizing Value From Broad Discovery Platforms Through Strategy and Strategic Partnering”\n\n\n\n\n\nDate:\n\n\n \n\n\nTuesday, June 22, 2021\n\n\n\n\n\nTime:\n\n\n \n\n\n1:10 pm ET\n\n\n\n\n\nFormat:\n\n\n \n\n\nFireside chat\n\n\n\n\n\nParticipants:\n\n\n \n\n\nRA Session II, President, Founder and CEO\n\n\n\n\nWebcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.\n\nAbout Taysha Gene Therapies \n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically impro...

More updates from Taysha Gene Therapies, Inc.